CSIMarket Company Name, Ticker, Competitors, else..


Bionexus Gene Lab Corp   (BGLC)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare


 

Bionexus Gene Lab Corp

BGLC's Financial Statements and Analysis



Bionexus Gene Lab Corp reported in the second quarter of 2024 net earnings per share of $0.01 an increase by -466.67 % year on year from $0.00 and an improvement compare to net loss per share of $-0.02 realized in previous quarter.


second quarter of 2024
Earnings Per Share Revenues
$ 0.01 $  2 Mill
$+0.01     $-1M     -23.07 %



Bionexus Gene Lab 's Revenue fell by -23.07 % in second quarter of 2024 (Jun 30 2024) year on year, to $2 million and declined by -17.1 % sequentially.


Bionexus Gene Lab is

More on BGLC's Income Statement



Bionexus Gene Lab 's net income of $0.199 million in the second quarter of 2024 increased from net loss of $-0.259 million II. Quarter a year ago.

Sequentially Company turn into Profitability from net loss of $-0.104 million recorded in previous quarter.

More on BGLC's Growth

Bionexus Gene Lab Inventories
Inventories declined by -11.39 % to $1.03 million from II. Quarter a year ago, sequentially inventories fell by -4.08 %. In Jun 30 2024 company's net cash and cash equivalents decreased by $0 million, capital expenditures fell by -0.014356530.54%, to $0 millions compare to same quarter a year ago

More on BGLC's Cash flow Statement


Bionexus Gene Lab Corp does not pay out common stock dividend.

In trailing twelve-month period Bionexus Gene Lab Corp payed $ -0.11 cash per share, on a free-cash flow basis .

Book value grew by 2.16 % sequentially to $0.54 per share.
Tangible Book value grew to $ 0.54 per share from $ 0.53.

Company repurchased 0.00 million shares or 0.00 % in Jun 30 2024.


• More on BGLC's Dividends

 Market Capitalization (Millions) 7
 Shares Outstanding (Millions) 18
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -2
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Bionexus Gene Lab Corp does not pay out common stock dividend.

In trailing twelve-month period Bionexus Gene Lab Corp had negative $ -0.11 cash flow per share, on a free-cash flow basis .

Book value grew by 2.16 % sequentially to $0.54 per share.
Tangible Book value grew to $ 0.54 per share from $ 0.53.

Company repurchased 0.00 million shares or 0.00 % in Jun 30 2024.


• More on BGLC's Balance Sheets

 Market Capitalization (Millions) 7
 Shares Outstanding (Millions) 18
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -2
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) -1
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Bionexus Gene Lab Corp Earnings

Financial Results Show Mixed Performance for Bionexus Gene Lab Corp in Q1 20242.

Bionexus Gene Lab Corp (BGLC) recently released its financial results for the fiscal period ending March 31, 2024, painting a mixed picture of the company's performance. While revenue saw a modest increase compared to the previous year, deficits per share grew and income per share declined. This trend, coupled with a larger net deficit realized by the company, has raised concerns among investors and analysts.
Specifically, BGLC reported a deficit per share of $-0.02 for the period, a significant increase from the $0.00 per share reported a year prior. Additionally, income per share fell from $0.02 to an undisclosed amount, indicating a decrease in profitability for the company. Despite a 0.195% increase ...

Bionexus Gene Lab Corp Reports Modest Growth in Top-line Revenue during Fiscal Q2 2023



Bionexus Gene Lab Corp (BGLC) recently released its financial results for the second quarter of 2023. In order to understand the implications of these results and their potential effects on the company's future, it is crucial to delve deeper into the figures and analyze them in the context of the overall medical laboratories sector.
Revenue Growth and Comparison:
During the second quarter of 2023, BGLC's revenue witnessed a slight increase of 3.289% to reach $2.57 million. This should be seen in relation to the corresponding period a year earlier, when the company generated $2.49 million in revenue. Furthermore, Q2 2023 revenue also recorded a sequential growth of 7.978% from $2.38 million....